重组人血管内皮抑素联合DCF方案新辅助化疗在进展期胃癌中的应用

目的 观察重组人血管内皮抑素(恩度)联合DCF方案新辅助化疗治疗进展期胃癌的临床疗效、毒副反应及术后并发症.方法 确诊的30例进展期胃癌均采用恩度联合DCF方案新辅助化疗治疗,每3周重复,于化疗结束后4周进行手术治疗.结果 临床有效率为66.7%,SD 8例(26.7%),PD 2例(6.7%).所有者均进行了手术,肿...

The Clinical Application of Recombination Human Endostatin Combined with DCF Regimen Neoadjuvant Chemotherapy in the Treatment of Advanced Gastric Cancer

Objective To investigate the clinical efficacy,the toxicities and the postoperative complications of recombination human endostatin and DCF regimen neoadjuvant chemotherapy in the treatment of advanced gastric cancer.Methods Thirty patients with advanced gastric cancer were treated with recombination human endostation and DCF regimen chemotherapy,repeated every 3 weeks.Surgery was performed after therapy.Results The response rates was 66.7%,SD was observed in 8 patients(26.7%),PD 2 patients(6.7%).All the patients were treated with surgery,the rate of tumor resection was 83.3%(25/30),and the radical resection rate was 46.8%(14/30);the laparotomy rate was 16.6%(5/30).No mortality was observed in the group,the main toxicities were neutropenia,nausea and vomiting.Conclusion The recombination endostatin combined with DCF regimen neoadjuvant chemotherapy in the treatment of advanced gastric cancer is effective,and the toxicities can be tolerated.